Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:55:12 EDT Fri 18 Apr 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

V:NGEN - Nervgen Pharma Corp. - https://www.nervgen.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NGEN - V0.32.96·3.000.52.96    3.36  1.65Apr 17Apr 1415 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolumeBuyerSellerMarkers
        
        
        
        
        
        
        
        
        
        

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2025-04-14 21:03C:NGEN2.94Prospectus ApprovedNervgen Pharma prospectus offering
2025-04-09 19:29C:NGEN2.87News ReleaseNervgen issues 564,500 shares under ATM program in Q1
2025-04-03 07:43C:NGEN3.30SEDAR MD & ASEDAR MD & A
2025-04-03 07:38C:NGEN3.30SEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2025-04-03 07:31C:NGEN3.30News ReleaseNervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates
2025-03-31 18:47C:NGEN2.87News ReleaseNervgen starts expanded access policy for NVG-291
2025-03-25 17:15C:NGEN2.65News ReleaseNervgen Pharma to hold virtual investor event April 9
2025-03-14 19:32C:NGEN2.72News ReleaseNervgen Pharma grants options to buy 545,000 shares
2025-02-18 19:46C:NGEN2.97News ReleaseNervgen Pharma grants options to buy 627,200 shares
2025-02-06 16:54C:NGEN2.86News ReleaseNervgen doses subject in phase 1b/2a NVG-291 trial
2025-01-02 16:41C:NGEN3.32News ReleaseNervgen enrolls final chronic subject in NVG-291 trial
2024-12-20 16:25C:NGEN3.00News ReleaseNervgen Pharma arranges ATM equity program
2024-11-14 08:31C:NGEN2.68News ReleaseNervGen Pharma Reports Q3 2024 Financial Results and Operational Updates
2024-11-14 08:05C:NGEN2.68SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-11-14 08:05C:NGEN2.68SEDAR Interim MD & ASEDAR Interim MD & A
2024-11-07 08:31C:NGEN2.52News ReleaseNervGen Pharma to Present at the Stifel 2024 Healthcare Conference
2024-11-04 19:29C:NGENSEDAR Final Short Form ProspectusSEDAR Final Short Form Prospectus
2024-11-04 13:45C:NGEN2.59SEDAR Preliminary Short Form ProspectusSEDAR Preliminary Short Form Prospectus
2024-10-28 15:53C:NGEN2.60SEDAR Annual Information FormSEDAR Annual Information Form
2024-09-30 15:48C:NGEN2.53News ReleaseNervgen still working on NVG-291 trial enrolment